Rallybio Corp (RLYB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $88.03M
Last updated: Nov 17, 2026 at 11:04 AM ET
Rallybio Corp (RLYB) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Rallybio reported EPS of -$0.48. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RLYB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 21 quarters below that had an estimate, RLYB beat 12, missed 8 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 284.62% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.48 | -$1.44 | -$1.44 - -$1.44 | N/A | N/A | -116.7% | 1 | 0 up, 0 down | Oct 27, 2026 | N/A |
| Jun 30, 2026 | -$1.09 | -$1.28 | -$1.28 - -$1.28 | +14.84% | Beat | N/A | 1 | 0 up, 0 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$1.46 | -$1.20 | -$1.20 - -$1.20 | -21.67% | Miss | N/A | 1 | 1 up, 0 down | May 13, 2026 | $212000 |
| Dec 31, 2025 | -$1.52 | -$1.23 | -$1.28 - -$1.20 | -23.94% | Miss | -708.0% | 2 | 0 up, 1 down | Mar 12, 2026 | $222000 |
| Sep 30, 2025 | $2.88 | -$1.56 | -$1.76 - -$1.36 | +284.62% | Beat | N/A | 2 | 0 up, 1 down | Nov 6, 2025 | $212000 |
| Jun 30, 2025 | -$0.22 | -$0.25 | -$0.26 - -$0.23 | +10.20% | Beat | N/A | 2 | 1 up, 1 down | Aug 7, 2025 | $212000 |
| Mar 31, 2025 | -$1.68 | -$2.28 | -$2.48 - -$2.08 | +26.32% | Beat | N/A | 2 | 1 up, 0 down | May 8, 2025 | $212000 |
| Dec 31, 2024 | $0.25 | -$0.30 | -$0.32 - -$0.28 | +183.33% | Beat | N/A | 3 | 2 up, 1 down | Mar 13, 2025 | $38000 |
| Sep 30, 2024 | -$2.08 | -$2.70 | -$3.28 - -$2.56 | +22.96% | Beat | N/A | 5 | 0 up, 0 down | Nov 7, 2024 | $299000 |
| Jun 30, 2024 | -$2.96 | -$2.86 | -$3.68 - -$2.00 | -3.50% | Miss | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | $299000 |
| Mar 31, 2024 | -$3.76 | -$3.68 | -$4.24 - -$2.88 | -2.17% | Miss | N/A | 5 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.50 | -$0.45 | -$0.52 - -$0.36 | -11.11% | Miss | N/A | 7 | 0 up, 0 down | Mar 12, 2024 | $228000 |
| Sep 30, 2023 | -$3.60 | -$3.98 | -$4.40 - -$3.84 | +9.55% | Beat | N/A | 7 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$3.68 | -$3.77 | -$4.16 - -$3.44 | +2.39% | Beat | N/A | 7 | 0 up, 0 down | Aug 8, 2023 | N/A |
| Mar 31, 2023 | -$3.44 | -$3.72 | -$4.40 - -$3.04 | +7.53% | Beat | N/A | 7 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$0.46 | -$0.60 | -$0.64 - -$0.50 | +23.33% | Beat | N/A | 5 | 0 up, 0 down | Mar 6, 2023 | N/A |
| Sep 30, 2022 | -$4.80 | -$4.32 | -$4.48 - -$4.16 | -11.11% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2022 | N/A |
| Jun 30, 2022 | -$4.56 | -$4.88 | N/A | +6.56% | Beat | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | N/A |
| Mar 31, 2022 | -$3.84 | -$3.76 | -$4.00 - -$3.20 | -2.13% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2022 | N/A |
| Dec 31, 2021 | -$0.42 | -$0.39 | -$0.43 - -$0.34 | -7.69% | Miss | N/A | 4 | 0 up, 0 down | Mar 15, 2022 | N/A |
| Sep 30, 2021 | -$2.96 | -$7.08 | -$8.48 - -$5.68 | +58.19% | Beat | N/A | 2 | N/A | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$2.80 | -$2.80 | N/A | 0.00% | In line | N/A | 2 | 0 up, 0 down | Sep 9, 2021 | N/A |
| Mar 31, 2021 | -$4.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 2, 2021 | N/A |
| Dec 31, 2020 | -$4.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Dec 31, 2019 | -$1.97 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | N/A |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.54, after -$8.55 the year before. It was -$1.97 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.54 | N/A |
| Dec 31, 2024 | -$8.55 | N/A |
| Dec 31, 2023 | -$11.22 | N/A |
| Dec 31, 2022 | -$13.66 | N/A |
| Dec 31, 2021 | -$10.29 | N/A |
| Dec 31, 2020 | -$4.11 | N/A |
| Dec 31, 2019 | -$1.97 | N/A |
Frequently Asked Questions About RLYB
What EPS do analysts expect from RLYB next quarter?
The consensus EPS estimate for Rallybio for the quarter ending Dec 31, 2026 is -$1.61 from 3 analysts.
How often does RLYB beat earnings estimates?
Rallybio beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +62.08%.
RLYB pages: Overview, Earnings, Forecast, Financials, Competitors